Leukemia Clinical Trials

Showing 3421-3440 of 5,235 trials

Concurrent Neoadjuvant Chemoradiotherapy Plus Durvalumab (MEDI4736) in Resectable Stage III NSCLC

NCT03694236

Combination treatment of Durvalumab with chemoradiotherapy is ongoing for head/neck cancer, renal cell carcinoma, melanoma, and non-small cell lung cancer (NCT02318771) and pancreatic cancer (NCT02305186).Combining Durvalumab with neoadjuvant chemoradiotherapy is a promising strategy to improve clinical outcome in stage III lung cancer. Using serial biopsied and surgically resected fresh tissue through the novel/high-throughput RNA sequencing technologies, we want to identify the change immune signature in tumor microenvironment of NSCLC patients after Durvalumab treatment. With hypothesis that PD-1 inhibitor as a component of neoadjuvant chemoradiotherapy followed by surgery could increase complete pathologic response rate and disease free survival, and overall survival, we suggest adding Durvalumab to neoadjuvant chemoradiation in stage II/III resectable NSCLC. And with immune marker study using FACS, whole exome sequencing, or RNAsequencing, we can find the potential predictive biomarker for anti-PD-L1 blockade. And in this study, we can get "whole" surgical specimen not biopsy sample after Durvalumab treatment so the analysis for immune marker, tumor microenvironment, and various tumor infiltrating immune cells and their changes will be available.

Potentially Resectable Stage II/IIIa NSCLC

Yonsei University39 participantsStarted Feb 2019

Seoul, South Korea

COMPLETEDPhase 2

A Study of Pemetrexed/Cisplatin as Pre-operative Treatment of Early Stage Nonsquamous Non-Small Cell Lung Cancer

NCT01165021

The purpose of this trial is to assess how well the combination of pemetrexed with cisplatin can reduce tumor size.

Non Small Cell Lung Cancer

Eli Lilly and Company19 participantsStarted Nov 2010

Milan, Italy • Novara, Italy • Orbassano, Italy +4 more locations

Concurrent Neoadjuvant Chemoradiotherapy Plus Durvalumab (MEDI4736) in Resectable Stage III NSCLC

A Study of Pemetrexed/Cisplatin as Pre-operative Treatment of Early Stage Nonsquamous Non-Small Cell Lung Cancer

Related Searches

Functional Lung Avoidance for Individualized Radiotherapy (FLAIR): A Randomized, Double-Blind Clinical Trial

Cost-effectiveness of Extracorporeal Life Support Treatment

Multi-CAR T Cell Therapy Targeting CD7-positive Malignancies

HIV and Sexually Transmitted Infection Prevention Intervention in the Northwest Territories

A Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Cancer Indications

A Study of Emibetuzumab in Non Small Cell Lung Cancer (NSCLC) Participants

A Study of Advanced or Metastatic Non-small Cell Lung Cancer

Safety And Efficacy Of Crizotinib (Regulatory Post Marketing Commitment Plan)

Sleep Hygiene and Relaxation Intervention to Improve Sleep and Fatigue for Children Receiving Maintenance Chemotherapy

Efficacy and Safety of SUBLIVAC Phleum for Immunotherapy of Grass Pollen-Allergy

Arthroscopic Assisted Lateral Soft Tissue Release for Hallux Valgus

Evaluating for Contact Allergies in Patients With Chronic Urticaria

Hsp90 Inhibitor AUY922 and Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV Non-Small Cell Lung Cancer

A Study of LY3039478 in Combination With Dexamethasone in Participants With T-ALL/T-LBL

CRUSH-PrEP for Women Project

Safety & Efficacy Study of EGF Cancer Vaccine to Treat Stage IV Biomarker Positive, Wild Type EGF-R NSCLC Patients

Bronchoscopy With Bronchoalveolar Lavage in Identifying Biomarkers of Response to Immune Checkpoint Inhibitors in Patients With Non-small Cell or Small Cell Lung Cancer

Treatment of Children CD19+ Leukemia and Non-Hodgkin Lymphoma With CD19-TriCAR-T/SILK Cell Therapy